Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A. Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression…”In the company’s words, NCT06270316 on ClinicalTrials.gov
- Tested for
- Fabry Disease
- Main trialPhase 1/2
- “The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.”In the company’s words, NCT06270316 on ClinicalTrials.gov
Other drugs for Fabry Disease
- Migalastat HClAmicus Therapeutics · Phase 3
- Pegunigalsidase alfaChiesi Farmaceutici S.p.A. · Protalix · Phase 2/3
- LucerastatIdorsia Pharmaceuticals Ltd. · Phase 3
- Agalsidase betaSanofi · Phase 3
- GZ/SAR402671Sanofi · Phase 3
- EXG110Guangzhou Jiayin Biotech Ltd · Phase 1/2
Coming up1
- 1 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Dec 2027 | Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026